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Abstract
Background: A devastating aspect of Alzheimer’s disease (AD) is the progressive deterioration of memory due to neuronal
loss. Amyloid precursor protein (APP) occupies a central position in AD and APP-derived amyloid-b (Ab) peptides are
thought to play a pivotal role in disease pathogenesis. Nonetheless, it is becoming clear that AD etiology is highly complex
and that factors other than Ab also contribute to AD pathogenesis. APP intracellular domain (AICD) is generated together
with Ab and we recently showed that AICD transgenic mice recapitulate pathological features of AD such as tau
hyperphosphorylation, memory deficits and neurodegeneration without increasing the Ab levels. Since impaired adult
neurogenesis is shown to augment memory deficits in AD mouse models, here we examined the status of adult
neurogenesis in AICD transgenic mice.
Methodology/Principal Finding: We previously generated transgenic mice co-expressing 59-residue long AICD fragment
and its binding partner Fe65. Hippocampal progenitor cell proliferation was determined by BrdU incorporation at 1.5, 3 and
12 months of age. Only male transgenic and their respective wilt type littermate control mice were used. We find age-
dependent decrease in BrdU incorporation and doublecortin-positive cells in the dentate gyrus of AICD transgenic mice
suggesting impaired adult neurogenesis. This deficit resulted from decreased proliferation and survival, whereas neuronal
differentiation remained unaffected. Importantly, this impairment was independent of Ab since APP-KO mice expressing
AICD also exhibit reduced neurogenesis. The defects in adult neurogenesis are prevented by long-term treatment with the
non-steroidal anti-inflammatory agents ibuprofen or naproxen suggesting that neuroinflammation is critically involved in
impaired adult neurogenesis in AICD transgenic mice.
Conclusion/Significance: Since adult neurogenesis is crucial for spatial memory, which is particularly vulnerable in AD,
these findings suggest that AICD can exacerbate memory defects in AD by impairing adult neurogenesis. Our findings
further establish that AICD, in addition to Ab, contributes to AD pathology and that neuroinflammation plays a much
broader role in AD pathogenesis than previously thought.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder characterized by a gradual decline in memory and
executive functions. Mounting evidence suggests Amyloid
precursor protein (APP) and presenilins are central molecules
in the pathophysiology of AD [1,2]. Aided by presenilins, APP
undergoes constitutive proteolysis to produce multiple frag-
ments including amyloid b (Ab) peptides, which form senile
plaques. A vast number of studies have shown that Ab plays a
pivotal role in the pathophysiology of AD [2] and it is thought
that Ab peptides, in an as yet uncertain form, trigger a cascade
of downstream deleterious events that eventually results in AD.
Ab peptides are shown to hyperphosphorylate tau [3], induce
neuronal cell death in vitro, and cause memory deficits in mice
[4]. They are also implicated in causing silent seizures [5] and
in the impairment of adult neurogenesis in AD mouse models
[6–10].
The process of neurogenesis occurs mostly during embryogen-
esis but also persists during adulthood in the subventricular zone
and subgranular zone (SGZ) of the hippocampus. There is
increasing evidence that adult hippocampal neurogenesis plays an
important role in learning and memory [11]. Increased adult
neurogenesis enhances hippocampal-dependent learning and
memory [12] whereas decreased neurogenesis impairs it [13].
Also, drugs that increase hippocampal neurogenesis also increase
learning and memory [14] and hippocampal neurogenesis is
known to decline with aging [15]. Adult neurogenesis is important
for maintaining spatial memory function [13,16], which is
characteristically lost in AD patients. Thus, impaired neurogenesis
is being recognized as a significant pathological feature of AD
since it can further exacerbate the memory decline caused by
neuronal loss.
Although, Ab peptides have been known to play a pivotal role in
AD pathology, it is becoming increasingly clear that not all aspects
of AD can be accounted for by Ab alone [17,18]. Findings from
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and preclinical observations suggest that non-Ab factors also
contribute to memory deficits in AD. The cleavage of APP by
presenilins, which generates Ab, also releases APP Intracellular
domain (AICD) from the membrane. AICD modulates gene
transcription in vitro [19,20], alters signaling pathways and exerts
deleterious effects in tissue culture cells [21,22], which could cause
AD-like features in vivo. Indeed, AICD expressing transgenic mice
recapitulate such AD pathologies as activation of glycogen
synthase kinase-3b (GSK3b), phosphorylation and aggregation of
Tau, deficits in working memory and abnormal neural activity and
silent seizures [23–25]. Interestingly, these pathologies were
observed without appreciable changes in APP metabolism or Ab
generation [24]. Since AICD levels are elevated in human AD
brains [24], these findings raise the possibility that AICD, in
addition to Ab, significantly contributes to AD pathogenesis.
In this study, we report that AICD transgenic mice also exhibit
impaired adult neurogenesis by reducing neuronal proliferation
and survival. This impairment is observed even in the absence of
endogenous APP demonstrating that AICD alone is capable of
inducing the deleterious effects. Importantly, the defective adult
neurogenesis is prevented by blocking neuroinflammatory changes
indicating that neuroinflammation plays a much broader role in
AD pathogenesis than previously thought.
Results
Adult hippocampal progenitor cell (HPC) proliferation is
reduced in AICD transgenic mice
We measured HPC proliferation in the SGZ by injecting male
AICD transgenic mice (line FeCc25) at 1.5, 3 or 12 months of age
daily with BrdU for 3 days. Mice were sacrificed 24 hours after the
last injection, brains were harvested, fixed and free-floating
sections were prepared. We used male mice in this study to avoid
the confounding effects of estrus cycle and gonadotrophins on
adult neurogenesis in female animals [26]. Brain slices were
immunostained with anti-BrdU antibody and BrdU-positive
(BrdU+) cells were quantified in the SGZ (defined as the region
spanning the border of granule cell layer and hilus with two cell
layers into the granule cell layer and hilus) of the entire rostro-
caudal extent of the hippocampus. At 1.5 months, the numbers of
BrdU+ cells in FeCc25 mice were similar to that observed in non-
transgenic control littermates (Fig. 1A,B). However, 3-month-old
FeCc25 mice exhibited reduced BrdU+ cells compared to wild-
type animals (Fig. 1C). Since FeCc25 transgenic mice co-express
AICD and Fe65 (which binds and stabilizes AICD), we performed
an analogous experiment on Fe27 transgenic mice, which express
Fe65 alone [23]. Fe27 mice showed a similar number of BrdU+
cells as the non-transgenic controls (Fig. 1C, E), indicating that
AICD is required to observe impaired HPC proliferation in 3-
month-old mice. The deficits in HPC proliferation were also
observed in 12-month-old AICD transgenic mice (p,0.05;
Fig. 1D, E). Animals older than 12 months were not studied
because at this stage even the wild-type mice showed a very low
level of adult neurogenesis. Together, these data suggest that
AICD impairs adult HPC proliferation in vivo.
Decreased hippocampal neurogenesis in AICD transgenic
mice
A majority of newborn cells in the SGZ of adult animals do not
survive, and the surviving cells differentiate into neurons or glia
[27]. To examine whether reduced HPC proliferation is also
accompanied by reduced neurogenesis, we immunostained the
brain sections with anti-doublecortin (DCX) antibody. DCX is a
microtubule binding protein that is expressed by immature
neurons but not by glia. At 3 months of age, wild-type mice
showed a large number of highly branched DCX+ cells in the
SGZ, with branch tips extending into the molecular layer (Fig. 2A).
By contrast, the staining was severally diminished in age-matched
FeCc25 mice and there was a decrease in the number of DCX+
cells (Fig. 2A, 2D) as well as in the extent of arborization (see
Fig. 2C). As observed above, the reduction in the number of
DCX+ persisted in 12-month-old mice (Fig. 2B, 2D). Collectively,
these results demonstrate that reduced HPC proliferation is
accompanied by decreased neurogenesis in AICD transgenic mice
and that these deficits are apparent at 3 months of age and
continue to at least 12 months of age.
AICD impairs cell survival but not cell differentiation in
hippocampus
We further corroborated the finding that AICD transgenic mice
show impaired HPC proliferation by determining the cell survival
and differentiation of the newborn cells. To measure cell survival,
we injected mice with BrdU for three consecutive days and
sacrificed them either one day or four weeks after the last injection
(Fig. 3A). Most newborn granular cells die during this time period
and the surviving cells differentiate into neurons or glia.
Quantification of BrdU+ cells showed that survival of the newborn
cells (the ratio of BrdU+ cells after 4 weeks to the BrdU+ cells after
1 day) was decreased (p,0.01) in FeCc25 mice (Fig. 3B). Roughly
19% and 14% of newborn cells in wild-type animals and in
FeCc25 mice survived after 4 weeks respectively.
We also determined the differentiation of newborn cells into
neurons and glia by performing double-immunostaining using
neuronal and astrocytic markers (Fig. S1). Brain sections were
incubated with anti-BrdU antibody and anti-NeuN antibody (to
mark mature neurons) or anti-GFAP antibody to identify
astrocytes. There were no significant differences in the percentage
of ‘NeuN+BrdU’ double-labeled cells and approximately half of
the newborn cells matured into neurons in both FeCc25 and wild-
type mice (Fig. 3C). Similarly, there were no significant differences
in the proportion of BrdU+ cells that matured into astrocytes
(Fig. 3D). Together, these results indicate that AICD decreases
HPC proliferation and survival without affecting cell differentia-
tion.
AICD impairs HPC proliferation in mice lacking APP
Adult neurogenesis is reduced in many mouse models of AD
and this reduction may be caused by multiple factors [reviewed in
6]. We previously showed that APP processing and Ab levels were
unchanged in 3-month-old FeCc25 mice compared to control
mice [24]. Thus, Ab probably plays no role in reduced adult
neurogenesis in FeCc25 animals. However, to address this issue
unambiguously, we crossed FeCc25 mice with APP knockout
animals and obtained AICD-expressing APP
2/2 mice. 3-month-
old FeCc25;APP
2/2 mice were injected with BrdU for 3 days,
brains were harvested on the 4
th day and sections were
immunostained for BrdU (Fig. 4A, B) or DCX (Fig. 4C). The
lack of APP did not seem to affect adult neurogenesis since the
number of BrdU+ cells in APP
2/2 animals (Fig. 4B) was similar to
that seen in wild-type animals (see Fig. 1B). However, there was a
small but significant decline (p,0.05) in the number of BrdU+
cells in the SGZ of FeCc25;APP
2/2 (Fig. 4 A, B). These results
unambiguously show that AICD, in the absence of endogenous
Ab, can impair HPC proliferation in vivo. We examined the DCX+
immature neurons in the SGZ of these mice and found that
FeCc25;APP
2/2 animals displayed a reduced number of DCX+
cells compared to APP
2/2 mice at 3 months of age (Fig. 4C, 4D).
AICD Impairs Neurogenesis
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c25;APP
2/2 animals (Fig. 4C, right panels).
We next determined the level of HPC proliferation in two
established mouse models of AD. APPPS1 mouse model expresses
‘Swedish’ mutant APP and M146L mutant presenilin [28] whereas
R1.40 mice express only ‘Swedish’ mutant APP [29]. We observed
a reduction in HPC proliferation in 3-month-old APPPS1 mice
but not in R1.40 animals (Fig. S2) even though both mouse models
show elevated levels of Ab. We do not know whether R1.40 mice
show neurogenesis defects at older ages but at a minimum, these
results show that an elevation in Ab alone does not necessarily
result in reduced neurogenesis. In any case, our findings confirm
Figure 1. AICD transgenic mice show decreased cell proliferation in the SGZ of hippocampus. Representative images of BrdU
immunostaining in the subgranular zone (SGZ) of the dentate gyrus performed on 1.5-mont-old (A) 3-month-old (C) and 12-month old (D) wild-type
and FeCc25 animals one day after the final BrdU injection (100 mg/kg). (A–B) At 1.5 mo there was no statistically significant difference in the number
of BrdU-labeled cells between wild-type and FeCc25 mice, quantified in (B). (E) Quantitative analysis of the total number of BrdU+ cells throughout
the entire rostro-caudal extent of the hippocampus in 3-month-old (top) and 12-month-old (bottom) animals reveal a statistically significant decrease
in the number of BrdU+ cells in the SGZ of FeCc25 mice compared to wild-type mice. (n=3, 4 and 4 for both wild-type and FeCc25 mice at ages 1.5
mo, 3 mo and 12 mo respectively. n=3 for Fe27 mice at 3 mo. * p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0011866.g001
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models and extend them to show that AICD, without Ab, is also
able to impair HPC proliferation.
Treatment with NSAIDs prevents the deficits in HPC
proliferation and neurogenesis
We next explored the potential mechanisms underlying the
inhibitory effects of AICD. Impairment of adult neurogenesis by
AICD in FeCc25 mice is probably not mediated by cell-
autonomous mechanisms because AICD expression is driven by
the CaMKIIa promoter, which is active only in mature neurons
[30]. However, since a number of factors including environmental
stress and neuroinflammation are known to inhibit adult
neurogenesis [31,32] we determined whether FeCc25 mice
showed signs of neuroinflammation. Unexpectedly, we observed
a dramatic increase in the recruitment of CD45+ microglia in 12
week-old FeCc25 mice compared to wild-type mice (Fig. 5A). We
also observed an increased expression of several proinflammatory
Figure 2. FeCc25 mice show a decreased number of immature neurons in the SGZ of dentate gyrus (DG). A–B, Coronal sections from 3
mo (A) and 12 mo (B) brains of wild-type and FeCc25 mice were immunostained for the immature neuronal marker doublecortin (DCX). There is an
abundance of immature neurons in the SGZ of the granule cell layer in both the supra- and infra-pyramidal blades of the DG. Compared to the wild-
type (top) there is a significant decrease in the number of DCX+ cells in the SGZ of FeCc25 mice (bottom). C, Magnification of the boxed region in (A)
show the diminished number of DCX+ cells in FeCc25 mice at 3 mo of age with a concomitant decline in dendritic number. (D) Quantitative analysis
of the total number of DCX+ cells throughout the entire rostro-caudal extent of the hippocampus in 3-month-old (left) and 12-month-old (right)
animals reveal a statistically significant decrease in the number of DCX+ cells in the SGZ of FeCc25 mice compared to wild-type mice. Scale bar
=100 mm. n=4 for all.
doi:10.1371/journal.pone.0011866.g002
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ment in FeCc25 mice was responsible for the reduction in adult
neurogenesis. To test this hypothesis, we treated mice with
ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), by
feeding animals a drug-containing diet (375 ppm) for 9 weeks
beginning at 3 weeks of age. Figure 5A shows that this regimen of
ibuprofen treatment completely blocked the recruitment and
activation of microglia in 3-month-old mice. Concomitantly, the
number of BrdU+ cells in ibuprofen-fed FeCc25 mice increased
significantly and were comparable to those seen in wild-type mice
(Fig. 5B, C). Compared to FeCc25 mice on the control diet,
ibuprofen-fed FeCc25 mice showed a 28% increase in the number
of BrdU+ cells in SGZ (p,0.05). The NSAID diet did not increase
the number of BrdU+ cells in wild-type mice (p=0.31). We also
performed DCX immunostaining on ibuprofen-treated animals
and noticed an increase in DCX+ cells in ibuprofen-treated
FeCc25 mice (Fig. 5D). After the ibuprofen treatment, the DCX+
cells in AICD transgenic mice were morphologically indistinguish-
able from those in wild-type mice (Fig. 5E).
Since ibuprofen is also known to possess off-target effects (non-
COX2), we used another NSAID, naproxen, to see whether it was
able to block neurogenesis defects in AICD mice. Like above,
AICD mice were fed naproxen-containing diet for 9 weeks and the
brains were analyzed (Figure 6 A–D). Indeed, treatment with
naproxen also resulted in increased BrdU incorporation in the
dentate gyrus (Figure 6A) and quantification showed that the
deficits were completely rescued (Fig. 6B). Similarly, naproxen-
treated mice showed increased DCX-staining that was comparable
to that seen in wild-type mice (Figure 6C, D). Thus, these data
establish that NSAID treatment rescues the deficits in adult
neurogenesis in AICD mice by blocking neuroinflammation.
Discussion
Here we show that AICD impairs adult hippocampal
neurogenesis in an age-dependent manner. Adult neurogenesis
was normal in 6-week-old AICD transgenic mice but was reduced
at 3 months of age and the impairment continued until at least 12
months of age. This impairment was due to decreased cell
proliferation and survival and not due to altered differentiation.
The defective neurogenesis is mediated by non-cell-autonomous
mechanisms involving proinflammatory changes. The important
finding of this study is that impaired adult neurogenesis in AD is
due to neuroinflammation and the novelty is that we provide
compelling evidence that overexpression of AICD impairs adult
neurogenesis without Ab.
An increasing number of studies indicate that adult neurogen-
esis plays an essential role in normal memory function [11,33].
Inhibition of adult neurogenesis impairs certain kinds of memory,
such as spatial learning [13,16]. Since the loss of spatial memory is
a prominent neurological feature of AD, we suggest that impaired
adult neurogenesis is especially detrimental in AD. Indeed, a vast
number studies have demonstrated deficits in adult neurogenesis in
amyloid-based mouse models of AD [6–10,31,34], although a
conflicting study has also been reported [35]. In AICD mice,
impaired neurogenesis is first observed at 3 months, which
precedes memory deficits by about 4–5 months [24]. Interestingly,
impaired adult neurogenesis is also detected much before the
appearance of other AD-features in APPswe/PS1dE9 [9] and
3xTgAD [14] mouse models of AD. Thus, deficient adult
neurogenesis is a significant pathological factor in AD and our
findings suggest that therapies against AD will be more effective
when supplemented with treatments that stimulate adult neuro-
Figure 3. AICD downregulates cell survival but does not affect differentiation of newly generated hippocampal cells. A, Experimental
design to measure HPC proliferation or HPC maturation. After the last BrdU injection, mice were sacrificed after 1 day (proliferation) or 1 month
(maturation) and HPC survival was quantified as the ratio of the number of BrdU+ cells present at 4 weeks post-BrdU to the number of BrdU+ cells
present one day after the last BrdU injection. (B) FeCc25 mice (13.7, SEM 0.02) showed a significant reduction in the cell survival potential compared
to wild-type mice (18.3, SEM 0.02) (* p=0.012, x
2 test). C–D, Quantitative analysis of the number of BrdU+ cells that mature into neurons (C) and
astrocytes (D) 4 weeks after birth. Analysis reveals that AICD does not influence the proportion of surviving cells that mature into neurons (NeuN+,
wild-type=54.8, SEM 0.04; FeCc25=56.6, SEM 0.1) or astrocytes (GFAP+, wild-type=14.0, SEM 0.02; FeCc25=15.1, SEM 0.03). n=3 for all.
doi:10.1371/journal.pone.0011866.g003
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PLoS ONE | www.plosone.org 5 July 2010 | Volume 5 | Issue 7 | e11866Figure 4. The effect of AICD is independent of other APP metabolites including Ab. A–B, Decreased cell proliferation in FeCc25;APP
2/2
mice compared to APP
2/2 mice. Photomicrograph reveals a reduced number of BrdU+ cells in the SGZ of FeCc25;APP
2/2 compared to APP
2/2 which
is quantified in (B) throughout the entire rostro-caudal extent of hippocampus. C, There was also a decrease in the number of immature neurons
(DCX+) in the FeCc25;APP
2/2 mice compared to APP
2/2. Insets are magnified on the right to reveal the decreased number of DCX+ cells and the
resulting dendritic branches in comparable regions of the hippocampus. (D) Quantitative analysis of the total number of DCX+ cells throughout
the entire rostro-caudal extent of the hippocampus in 3-month-old animals reveal a statistically significant decrease in the number of DCX+ cells in
the SGZ of FeCc25; APP
2/2 mice compared to APP
2/2mice.* p,0.05 (Student’s T-test). n=3 for all.
doi:10.1371/journal.pone.0011866.g004
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in FeCc25 mice. A, CD-45 immunohistochemistry showed that ibuprofen treatment for 2 months (right) can decrease neuroinflammation seen in
FeCc25 mice compared to wild-type (WT) mice (left) at 3 months of age. B–C, Ibuprofen treatment rescued decreased adult hippocampal cell
proliferation in FeCc25 mice at 3 months, quantified in C. D–E, The number of immature neurons detected by doublecortin immunoreactivity was
also increased in FeCc25 mice (bottom) compared to wild-type mice (top) after ibuprofen treatment. Comparable hippocampal regions are identified
in box D and enlarged in E for wild-type (left) and FeCc25 mice (right). Error bars represent S.E.M. Scale bar =100 mm. n=4 for untreated wild-type
and FeCc25 mice and n=3 and 4 for ibuprofen treated wild-type and FeCc25 mice respectively.
doi:10.1371/journal.pone.0011866.g005
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PLoS ONE | www.plosone.org 7 July 2010 | Volume 5 | Issue 7 | e11866Figure 6. Naproxen treatment also rescued defective adult neurogenesis. A–B, Naproxen treatment rescued decreased adult hippocampal
cell proliferation in FeCc25 mice at 3 months, quantified in B. C–D, The number of immature neurons detected by doublecortin immunoreactivity
was also increased in FeCc25 mice (bottom) compared to wild-type mice (top) after naproxen treatment. Comparable hippocampal regions are
AICD Impairs Neurogenesis
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(such as anti-inflammatory drugs). Indeed, our preliminary studies
show that NSAID treatment improves working memory deficits in
the Y-maze paradigm in older (.14 month) AICD transgenic
mice.
The finding that treatment with ibuprofen or naproxen
prevented neurogenesis defects is of relevance to AD and supports
the potential of NSAIDs as prophylactic therapeutic agents [36].
How AICD overexpression results in sustained neuroinflammation
is currently under investigation but our preliminary findings
suggest that AICD activates stress-kinase pathways and upregu-
lates expression of proinflammatory cytokines. Increased levels of
proinflammatory cytokine are reported in serum and CSF from
AD patients [37,38] and neuroinflammation is recognized as a
significant pathological event in AD [39,40]. A mutation in
presenilin that alters APP processing inhibits adult neurogenesis in
vivo by activating the microglia and elevating the cytokine levels
[31]. Proinflammatory conditions are known to downregulate
neurogenesis and blocking inflammation has been shown to
restore impaired neurogenesis [32]. At present the reasons why
proinflammatory environment impairs proliferation and survival
more potently but leaves neuronal maturation more or less intact
are not clear. Multiple studies have shown the inhibitory effects of
individual inflammatory factors (such as TNF-a, IFN-c, IL-6) on
proliferation but variable effects on maturation [reviewed in 41].
NPC proliferation is orchestrated by temporal and spatial cues and
involves expression of various transcription factors. It seems likely
that NPC proliferation is more sensitive to the gene expression
changes brought about by proinflammatory cytokines. In any case,
chronic neuroinflammation in AD is likely to impair adult
neurogenesis and aggravate the loss of hippocampal neurons.
Interestingly, retrospective epidemiological studies [36] have
shown that long-term use of NSAIDs exert a protective effect
against developing AD (although short-term prospective use of
NSAID was not protective) and this effect is proposed to be
mediated by modulation of Ab levels [42]. Since both drugs,
ibuprofen and naproxen, protected against AICD-induced defects
in adult neurogenesis, we propose that NSAIDs exert beneficial
effects independent of Ab modulation. Although our data show
that inflammation plays a pivotal role in impaired neurogenesis, it
is possible that AICD impairs neurogenesis also by stimulating
GSK-3b activity [23]. Activation of GSK-3b alters the wnt
signaling pathway and perturbs neurogenesis in mice [43,44] and
in AD patients [45].
The observation that AICD transgenic mice lacking Ab exhibit
impaired neurogenesis further strengthens the evidence that AICD
also contributes to AD pathology. Although a vast amount of data
support the pivotal role of Ab peptides in AD pathogenesis [1,2], it
has become clear that AD etiology is complex and that a single
causative agent cannot account for all of the available data
[17,18]. AICD causes apoptosis in vitro [21] and induces tau
hyperphosphorylation and aggregation, aberrant neuronal activ-
ity, memory deficit and neurodegeneration in vivo [24,25]. Because
AICD levels are also elevated in human AD brains [24], we had
hypothesized that AICD makes significant contributions to AD
pathogenesis, and the present study further supports this
hypothesis. Interestingly, a recent study showed that AICD
signaling occurs predominantly through the amyloidogenic
processing of APP [46]. This raises the possibility that the harmful
effects of amyloidogenic processing are mediated by both
increased Ab as well as elevated AICD (Fig. 6E) and may explain
the disappointing results from Ab-focused clinical trials. Future
studies are needed to assess the individual contribution of each
peptide to AD pathogenesis.
In conclusion, our study shows that AICD transgenic mice
exhibit impaired adult hippocampal neurogenesis in an Ab-
independent manner. More importantly, NSAID treatment had a
protective effect against the neurogenesis defects. Together, these
findings provide evidence for non-amyloid mechanisms that
potentially exacerbate neuronal loss in AD and suggest that




All experiments were approved by the Institutional Animal Care
and Use Committee of The Cleveland Clinic (Protocol Number:
08355).
Transgenic mice
Transgenic mice co-expressing the AICD-59 and Fe65 (FeCc25
line) or Fe65 alone (Fe27) in C57BL/6 background have been
described previously [23,24,47]. Both transgenes are active in the
brain under the control of the CAMKIIa promoter. For all
experiments non-transgenic littermates or C57BL/6 mice were
used as wild-type controls. APP
2/2 have been described in detail
previously [48] APPPS1 and R1.40 animals have been previously
described in detail [28], [29]. To generate FeCc25/APP
2/2 mice
that would express AICD59 and Fe65 on APP null background,
FeCc25 hemizygous mice were bred with APP
+/2 mice to obtain
FeCc25/APP
+/2 mice in the F1 generation. Subsequently,
FeCc25/APP
+/2 mice were bred with APP






All animals were housed under standard conditions with 4–5 mice
per cage. Table 1 shows the various genotypes of mice used with
their treatments groups.
5-Bromo-2-deoxyuridine injection and tissue preparation
To avoid the effects of gender and gonadotropic hormones on
adult neurogenesis, only male mice were used throughout the
study. To determine cell proliferation, mice were injected once
daily with 5-Bromo-2-deoxyuridine (BrdU; 100 mg/kg, i.p.) for
three consecutive days. On the day following the last BrdU
injection, animals were anesthetized and transcardially perfused
with ice-cold phosphate-buffered saline (PBS) followed by PBS
containing 4% paraformaldehyde. Brain were removed and fixed
in PBS containing 4% paraformaldehyde overnight at 4uC,
cryoprotected in 30% sucrose in PBS, embedded using OCT
compound (Sakura Finetek, Torrance, CA, USA) and stored at
280uC. To determine long-term cell survival and maturation,
identified in box C and enlarged in D for wild-type (left) and FeCc25 mice (right). Error bars represent S.E.M. Scale bar =100 mm. n=4 for WT, FeCc25
and WT with naproxen and n=6 for FeCc25 with naproxen. E. A schematics of how amyloidogenic processing of APP could bring about deleterious
effects via both AICD and Ab peptides. Amyloidogenic processing [1] of APP generates Ab and promotes AICD signaling [45]. Ab peptides impair
adult neurogenesis possibly by causing [2] an imbalance in GABAergic and Glutamatergic transmissions [10] whereas AICD does so by inducing [3]
neuroinflammation (this study). Multiple studies have also shown that both Ab and AICD peptide fragments cause [4] other AD-pathological
(including tau hyperphosphorylation, neuronal cell loss, silent seizures, memory deficits) features in mice (dashed arrows).
doi:10.1371/journal.pone.0011866.g006
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brains were processed as described above.
Immunohistochemistry
Hemi-brains were fixed overnight in 4% paraformaldehyde in
PBS, sunk in 30% sucrose and embedded in OCT. 30 mm sagittal
sections were cut and every 12
th section was used. Antibodies used
were BrdU (Abcam, 1:500) and doublecortin (SantaCruz, 1:1000).
Remaining details are given in Supplemental Methods S1.
Stereological counts
The total number of BrdU+ or DCX+ cells in the subgranular
zone of the dentate gyrus was quantified using unbiased
stereological methods. BrdU+ or DCX+ cells were counted from
every sixth section using a 40X objective throughout the entire
rostro-caudal extent of the dentate gyrus (bregma 21.0 mm to
22.80 mm). Cells were counted from both halves of the brain
within the granular cell layer (GCL) and adjacent SGZ up to a
two-cell body-wide zone along the border between the GCL and
the hilus. The experimenter counting the cells was blinded to the
genotype and experimental modification of the mice. The total
number of cells was obtained by multiplying the number of BrdU+
or DCX+ cells with inter section interval and adding them
together for the entire hippocampus.
Non-steroidal anti-inflammatory drug (NSAID) diet
Ibuprofen or naproxen (both from Sigma Aldrich) was
formulated into standard animal chow by Research Diets at a
final concentration of 375 ppm. Male FeCc25 and non-transgenic
littermates were fed drug-supplemented or control chow for 9
weeks. Mice were killed at the end of the experimental period and
processed for histology or biochemical analyses. For neurogenesis
assays, animals were injected with BrdU for three consecutive days
before sacrificing as described above.
Statistics
Statistical analysis was performed using GraphPad prism 3.1.
The results are expressed as mean 6 standard errors of mean
(SEM).
Rest of the protocols is described in Supplemental Methods
(Methods S1).
Supporting Information
Methods S1 Supplemental Methods
Found at: doi:10.1371/journal.pone.0011866.s001 (0.03 MB
DOC)
Figure S1 Differentiation of newborn granular cells into neurons
and astrocytes. Mice were injected with BrdU and sacrificed one
month after the last injection. Brains were harvested and free-
floating sections were incubated with anti-BrdU antibody with
anti-NeuN antibody (A) or anti-GFAP antibody (B). Confocal
image analysis was used to score the coexpression of BrdU (green)
with the neuronal marker NeuN (A, red) or the astrocyte marker
GFAP (B, red).
Found at: doi:10.1371/journal.pone.0011866.s002 (6.99 MB TIF)
Figure S2 Decreased neurogenesis in other mouse models of
AD. A, Thioflavin-S staining of 3-month-old animals showed
increased plaque density in APPPS1 animals but a complete
absence in FeCc25 transgenic animals. B, BrdU immunostaining
on 3-month-old animals showed decreased cell proliferation in
APPPS1 mice similar to FeCc25 mice. R1.40 animals do not show
a decline and behaved similar to WT animals. C, Quantification of
BrdU counts throughout the entire hippocampus revealed a
significant decrease in cell proliferation for both FeCc25 and
APPPS1 animals compared to R1.40 and WT mice.
* p,0.05
ANOVA. N=4 for WT and FeCc25 and 3 for APPPS1 and
R1.40. Scale bar =100 mm
Found at: doi:10.1371/journal.pone.0011866.s003 (3.53 MB TIF)
Table 1. Study Design.
Genotype Age (month) Treatment Test (marker) Animals (n)
Wild Type 1.5 Regular Chow AHP Proliferation (BrdU) Immature Neuron (DCX) 3
3 Regular Chow AHP Proliferation (BrdU) Immature Neuron (DCX) 4
Regular Chow Survival/Maturation (BrdU/NeuN/GFAP) 3
Ibuprofen AHP Proliferation (BrdU) Immature Neuron (DCX) 3
Naproxen AHP Proliferation (BrdU) Immature Neuron (DCX) 4
12 Regular Chow AHP Proliferation (BrdU) Immature Neuron (DCX) 4
FeCc25 1.5 Regular Chow AHP Proliferation (BrdU) Immature Neuron (DCX) 3
3 Regular Chow AHP Proliferation (BrdU) Immature Neuron (DCX) 4
Regular Chow Survival/Maturation (BrdU/NeuN/GFAP) 3
Ibuprofen AHP Proliferation (BrdU) Immature Neuron (DCX) 4
Naproxen AHP Proliferation (BrdU) Immature Neuron (DCX) 6
12 Regular Chow AHP Proliferation (BrdU) Immature Neuron (DCX) 4
Fe27 3 Regular Chow AHP Proliferation (BrdU) Immature Neuron (DCX) 3
App2/2 3 Regular Chow AHP Proliferation (BrdU) Immature Neuron (DCX) 3
FeCc25;App2/2 3 Regular Chow AHP Proliferation (BrdU) Immature Neuron (DCX) 3
APPPS1 3 Regular Chow AHP Proliferation (BrdU) 3
R1.40 3 Regular Chow AHP Proliferation (BrdU) 3
Age (months) represents the time when BrdU injection was carried out. All Ibuprofen and Naproxen treatments were for 9 weeks terminating at 3 months of age. n
represents number of animals.
doi:10.1371/journal.pone.0011866.t001
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